Lymphocyte-depleted classical Hodgkin lymphoma (LD-cHL) is a rare histologic subtype of classical Hodgkin lymphoma. This population-based study aimed to describe the clinical characteristics and prognostic factors of LD-cHL using data from the SEER registry.LD-cHL patients were older (median age 55 years, IQR: 37–72) than those with other subtypes (median age 38 years, IQR: 25–58; p 60 years. Chemotherapy receipt was associated with higher survival rates across all age groups.In subgroup analyses limited to patients who received chemotherapy, LD-cHL remained associated with inferior survival compared with other subtypes. Lymphoma-specific survival analysis yielded 5-year rates of 88.9%, 84.3%, and 60.5% in the 60 years groups, respectively.This study confirms that LD-cHL is associated with older age, advanced stage at presentation, and relatively poor survival in real-world settings. Further studies with central pathological review and more detailed clinical data are needed to improve the understanding and management of this rare subtype.
Lyu et al. (Sun,) studied this question.